2012-11-09 08:45:13 -

LUND, SWEDEN -- (Marketwire) -- 11/09/12 --



· Laquinimod - Teva to initiate a new Phase III study in the US at
year-end
- milestone payment of USD 5 M received following a
submitted
application for regulatory approval in Europe
- Crohn's Phase II data presented at the UEGW conference





· TASQ - biomarker data presented at the ESMO conference
- Ipsen to initiate two new clinical Phase II studies:
maintenance therapy for prostate cancer and a study of other types of
cancer



· ANYARA - Phase III study results to be presented Q1 2013



· 57-57 - clinical trial of systemic sclerosis/scleroderma is
in progress



· ISI - project proceeding as planned



· Net sales: SEK 136.4 M (231.3)



· Operating loss: SEK 168.7 M (loss 6.2)



· Loss after tax: SEK 175.1 M (loss: 1.3)



· Loss per share for the period: SEK 2.54 (loss: 0.02)



This report is also available at www.activebiotech.com : www.activebiotech.com



Active Biotech AB Interim report January - September 2012:
hugin.info/1002/R/1656396/535516.pdf : hugin.info/1002/R/1656396/535516.pdf



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:



(i) the releases contained herein are protected by copyright and
other applicable laws; and



(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.



Source: Active Biotech via Thomson Reuters ONE



[HUG#1656396]




For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46 19 20 95

Hans Kolam
CFO
Tel: +46 (0)46 19 20 44

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00